This slide show highlights some of the most read stories on Cancer Network in 2016, including guidelines on surgical margins in DCIS, a study on serum vitamin D levels in breast cancer patients, and more.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Related Content

Understanding Palliative and End-Of-Life Care in Oncology

Julie M. Vose, MD, MBA

September 16th 2025

Article

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD

September 16th 2025

Podcast

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese

September 16th 2025

Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD

September 16th 2025

Podcast

Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese

September 16th 2025

Article

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

Our Most Read Cancer Stories of 2016

Newsletter